Company profile

AbelZeta Pharma, Inc.

Privately held: no public share price (Formerly Cellular Biomedicine Group (Nasdaq: CBMG from 2014); went private via a management/investor-led buyout completed February 2021, then renamed to AbelZeta Pharma, Inc. in Nov 2023 after spinning off its stem-cell business (prnewswire CBMG-name-change release). Currently a privately-held clinical-stage CAR-T/TIL company with centers in Rockville, MD and Shanghai; legacy ticker CBMG is retained as a historical identifier only, not an active listing. Sources: https://clinicaltrials.gov/study/NCT05521802 Entity resolved by asset-pipeline-v2.)

Assets

(1 total)

1Total Assets

0Approved

0Phase 3 / Filed

1Phase 1–2 / Early

1Diseases

Showing 1 of 1 assets

		Target & Modality
Trovocabtagene autoleucel (C-CAR088)	Phase 2	BCMACell therapy	Multiple Myeloma

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.